Aspen Pharmacable Holdings Reports Earnings Per Share of 795.9 Cents and Revenue of R34.8 Billion
Aspen Pharmacare Holdings reported earnings per share (EPS) of 795.9 cents for the fiscal year, alongside revenue reaching ZAR 34.8 billion. The results reflect strong performance across its operations in pharmaceutical manufacturing and distribution. The company's financials highlight continued growth amid a competitive market landscape. Additionally, Merck has signed licensing agreements with several companies including Viatris to develop new HIV treatments, which may influence the broader sector dynamics for Aspen Pharmacare Holdings as it competes globally.
Topics: earnings_report pharmaceuticals